MedTrace Logo

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

NCT04482608 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 671

Last updated 2020-07-27

No results posted yet for this study

Summary

Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC). The efficacy and survival of patients with dMMR/MSI-H status received palliative chemotherapy have not clear yet. In this study, the investigators observed the efficacy and survival of dMMR/MSI-H status mCRC patients received palliative first-line chemotherapy.

Conditions

  • Colorectal Cancer Metastatic
  • Mismatch Repair Deficiency
  • Microsatellite Instability High

Sponsors & Collaborators

  • The Second Affiliated Hospital of Kunming Medical University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Ying Jin, MD.,PhD · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-04-01
Completion
2020-06-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04482608 on ClinicalTrials.gov